FUJIFILM Cellular Dynamics announced on March 17, 2021 that Sana Biotechnology, a US-based biotechnology company focused on creating and delivering engineered cells, has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics' induced pluripotent stem cell (iPSC) platform for the development of commercial cell therapies. Under the terms of the agreement, FUJIFILM Cellular Dynamics will provide Sana with iPSC cell lines while maintaining intellectual property rights, FUJIFILM Cellular Dynamics said in a company press release. Sana will be authorized to use the iPSC cell lines for the research and development, clinical and commercial manufacture, and commercialization, of the cell therapies derived from the lines.